Brief: Liminatus Pharma Says Iba101 Advances Toward Human Trials In U.S.& Korea
24/06/2025 20:42
June 24 (Reuters) - Liminatus Pharma Inc LIMN.O: LIMINATUS PHARMA INC - IBA101 ADVANCES TOWARD HUMAN TRIALS IN U.S. AND KOREA - SEC FILING Source text: [ID:n0001104659-25-062058] Further company coverage: LIMN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminatus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Liminatus Pharma Announces Reverse Stock Split Of Its Common Stock
Brief: Liminatus Pharma Announces Planned Phase 1 Clinical Trial Of Iba101, A Next-Generation Cd47 Blocking Antibody
Brief: Liminatus Pharma Enters Settlement Agreement With Clear Street LLC